• CP-673451: Biomarker-Aware PDGFR Research

  2026-09-16

  CP-673451 is a selective PDGFRα/β inhibitor for dissecting receptor signaling, angiogenesis, and tumor biology. This guide develops a biomarker-aware assay strategy that connects PDGFR pharmacology with ATRX-deficient glioma research without overstating translational evidence.

• CLCC1 and Herpesvirus Nuclear Egress Fusion

  2026-09-15

  A 2024 bioRxiv preprint identifies the host factor CLCC1 as essential for the membrane-fusion step of herpes simplex virus 1 nuclear egress. The study separates viral NEC-driven budding from host-dependent fusion and connects herpesvirus capsid export with nuclear pore complex membrane insertion, providing a framework for investigating host-controlled stages of infection.

• Thiamet G Workflow for O-GlcNAc Studies

  2026-09-15

  Thiamet G provides a controlled way to elevate protein O-GlcNAcylation in cell, disease, and mechanistic assays. This workflow connects tauopathy research and leukemia studies with a carefully bounded extension into trophoblast ferroptosis and preeclampsia research.

• EZ Cap™ OVA mRNA: Designing Interpretable Immune Assays

  2026-09-14

  Learn how EZ Cap™ OVA mRNA can function as a standardized antigen-expression input for separating delivery performance, protein expression enhancement, and inflammatory biology. This article connects assay design to recent low-inflammation mRNA delivery research while emphasizing practical controls and interpretation.

• Inducing Right Ventricular-Like Cardiomyocytes from hPSCs

  2026-09-14

  Saito et al. developed a differentiation strategy that shifts human pluripotent stem cell cardiac progenitors toward an anterior second heart field-like state and produces right ventricular-like cardiomyocytes. The resulting cells differed from left ventricular-like controls in gene expression, spontaneous contraction, calcium handling, and cell size, providing a useful framework for chamber-specific disease modeling.

• BEND Lipids Improve mRNA Delivery and Gene Editing

  2026-09-13

  The reference study introduces branched endosomal disruptor lipids that improve lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes. By linking terminal branching to enhanced endosomal penetration, the work provides a rational design strategy for hepatic gene editing and T-cell engineering.

• LY2109761: TGF-β Signaling Research Workflows

  2026-09-12

  LY2109761 enables controlled interrogation of TGF-β-driven phosphorylation, cell-cycle arrest, tumor behavior, and fibrotic responses. This workflow-focused guide connects receptor inhibition with Smad2/3, CDC25A, radiosensitivity, and assay troubleshooting for reproducible preclinical research.

• ATRX Loss Sensitizes Glioma Cells to PDGFR Inhibitors

  2026-09-11

  Pladevall-Morera and colleagues identified a genotype-associated drug vulnerability in high-grade glioma: ATRX-deficient cells were more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-intact counterparts. The study also found enhanced toxicity when selected RTK inhibitors were combined with temozolomide, supporting ATRX status as a factor for interpreting targeted-therapy studies.

• PAD4-IN-2 TFA: An Assay-Design Guide

  2026-09-11

  PAD4-IN-2 TFA, also known as Compound 5i TFA, is a tumor-targeted PAD4 inhibitor for studying H3 citrullination, NET biology, metastasis, and immune remodeling. This guide focuses on experimental decision-making: how to distinguish direct tumor-cell effects from neutrophil-mediated mechanisms and select interpretable assays.

• BV6: From IAP Biology to Translational Design

  2026-09-10

  BV6 is more than a compound for apoptosis assays: it is a mechanistic probe for testing how IAP-dependent survival shapes treatment response. This thought-leadership analysis connects BV6-mediated IAP antagonism with apoptosis induction, radiosensitization, chemotherapy response, and disease-model design while using recent ovarian cancer muscle research to clarify what pathway modulation can—and cannot—establish. The result is a practical framework for translational researchers building evidence beyond conventional product-page claims.

• Anlotinib Hydrochloride in Angiogenesis Assays

  2026-09-10

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor suited to mechanism-led angiogenesis workflows, combining receptor-level validation with migration and tube-formation readouts. This guide translates its VEGFR2, PDGFRβ, and FGFR1 activity into practical assay design, comparative studies, and troubleshooting strategies for cancer research.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-09

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal cell subpopulations. The model reproduced clinically relevant tumor–stroma interactions, altered gene-expression programs, and patient- and drug-specific treatment responses, providing a stronger platform for personalized preclinical testing than epithelial organoids alone.

• BMS 599626 Dihydrochloride: EGFR/HER2 Workflow

  2026-09-09

  Build sharper EGFR and HER2 experiments with a dual-receptor inhibitor designed for phosphorylation, proliferation, and xenograft studies. This workflow also shows how to distinguish receptor-driven cytostasis from genuine senolysis when adapting machine-learning-guided assay concepts.

• Pulchinenoside B4 Targets CD1d–NLRP3 in Colitis

  2026-09-08

  A 2025 study shows that Pulchinenoside B4 protects against DSS-induced colitis through a macrophage-centered CD1d–NLRP3 mechanism. By combining genetic models, cell-type analysis, biolayer interferometry, and CETSA, the authors connect CD1d modulation with the AKT–STAT1–PRDX1–NF-κB axis and inflammasome control.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-08

  Masitinib (AB1010), SKU A2942, provides a DMSO-compatible tool for controlled KIT, PDGFRα, and PDGFRβ inhibition in cellular and biochemical research. It is suited to cancer biology, mastocytosis research, and mast-cell assays, but should not be used as a broad-spectrum kinase inhibitor or in aqueous and ethanol-based workflows.

8455 records 1/564 page Next 12345 下5页 Last page